Evidence map›Paper›PMID 38938237›Full record

ArticleJACC. Advances2023

Sacubitril/Valsartan and Cognitive Outcomes in Heart Failure With Reduced Ejection Fraction.

Prabhjot K Grewal, Alan Abboud, Evangelos Pavlos Myserlis, Marc E Goldschmidt, Javed Butler, Hal A Skopicki, Andreas P Kalogeropoulos

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Observational
  4. Review
  5. Article
  6. Our knowledge about atrial fibrillation steadily increases.European heart journal. Cardiovascular pharmacotherapy · 2025
    Article
  7. Article
  8. The Impact of Cognitive Impairment on Cardiovascular Disease.Journal of the American College of Cardiology · 2025
    Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Prabhjot K GrewalDepartment of Medicine, Stony Brook University, Stony Brook, New York, USA.
Alan AbboudRenaissance School of Medicine, Stony Brook University, Stony Brook, New York, USA.
Evangelos Pavlos MyserlisDepartment of Neurology, Medical University of South Carolina, Charleston, South Carolina, USA.
Marc E GoldschmidtDivision of Cardiology, Department of Medicine, Stony Brook University, Stony Brook, New York, USA.
Javed ButlerBaylor Scott & White Research Institute, Dallas, Texas, USA.
Hal A SkopickiDivision of Cardiology, Department of Medicine, Stony Brook University, Stony Brook, New York, USA.
Andreas P KalogeropoulosDivision of Cardiology, Department of Medicine, Stony Brook University, Stony Brook, New York, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Recent trial data refute concerns about neurocognitive off-target effects of neprilysin inhibition with sacubitril and suggest benefit in patients with heart failure and ejection fraction >40%. We hypothesized that sacubitril/valsartan is associated with improved cognitive outcomes in patients with heart failure and reduced ejection fraction (HFrEF). Objectives: The purpose of this study was to compare 3-year cognitive outcomes in patients with HFrEF who receive sacubitril/valsartan vs angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). Methods: Retrospective cohort study of: 1) 11,313 adults with HFrEF (International Classification of Diseases-10th Revision-Clinical Modification [ICD-10-CM] codes: I50.2 or I50.4) started on sacubitril/valsartan between 1/1/2015 and 12/31/2019; and 2) 11,313 propensity matched patients receiving ACEI/ARB during that time. Data were obtained from the TriNetX Research Network, encompassing 41 health care organizations in the United States. Primary endpoint was the composite of cognitive decline (ICD-10-CM: R41.8), dementia (ICD-10-CM: F01-F03), and Alzheimer's disease (ICD-10-CM: G30). Results: At 3 years, 858 patients on sacubitril/valsartan met the primary endpoint vs 1,209 on ACEI/ARB (3-year incidence: 10.7% vs 15.0%; HR: 0.69; 95% CI: 0.63-0.75; Conclusions: Sacubitril/valsartan was associated with lower 3-year rates of neurocognitive disorders when compared to ACEI/ARBs in patients with HFrEF.

Indexed as

Alzheimer’s diseasecognitive declinedementiaheart failureneprilysinsacubitril/valsartan

Identifiers

PMID38938237
PMCPMC11198036

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.